2 recruiting. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Asciminib single agent: new trials by email Literature Review of Asciminib single agent trials Research Report on Asciminib single agent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Asciminib single agent - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-04-28 | 2026-10-15 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Blast Crisis (1) · Bronchiolitis Obliterans Syndrome (1) · Leukemia (1) · Myeloproliferative Disorders (1)
Brazil (2) · Canada (2) · China (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Poland (2) · South Korea (2) · Spain (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Bulgaria (1)
2023 (1), 2025 (1)